View More Recent Stories
-
Jefferies Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
-
EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c
-
TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
-
EyePoint Pharmaceuticals (EYPT) to Highlight DURAVYUTM Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
